Worldwide, hepatitis B virus is the major risk factor for hepatocellular carcinoma (HCC), owing to its high prevalence in the developing world. Hepatitis B virus vaccination programs have and will ...

Hepatocellular carcinoma (HCC) is a significant global health concern, particularly in regions like the Asia-Pacific, where chronic viral hepatitis and liver diseases contribute to its high incidence ...

It offers a non-invasive approach and has broad clinical relevance in cancer management. This comprehensive review primarily ...

前言一年一度的肿瘤领域盛会——2024年欧洲肿瘤内科学会亚洲年会（ESMO ...

2.1 上海诊疗肝癌流行病学趋势变化（2016—2021年） 2016—2021年，上海市级医院共收治肝癌病人98 960例，其中首次手术病人42 ...

Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

Hepatocellular carcinoma (HCC) is the most common type of liver cancer and ranks among the leading causes of cancer-related deaths globally. Traditional treatment methods, including surgical resection ...

Hepatocellular carcinoma (HCC) is one of the most fatal malignancies. Epigenetic mechanisms have revealed that noncoding RNAs ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the ...

New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) PHILADELPHIA, Nov. 8, 2024 /PRNewswire/ -- Carisma ...